Vorolanib is under clinical development by Xcovery Holding and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vorolanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vorolanib overview

Vorolanib (X-82) is under development for the treatment of wet age-related macular degeneration, solid tumors including epithelial ovarian adenocarcinoma, metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction, small cell lung cancer, non-small cell lung cancer, thymic carcinoma, renal cell carcinoma, pancreatic neuroendocrine tumors, metastatic renal cell carcinoma, metastatic mucosal melanoma and advanced solid tumors. The drug candidate is administered orally. X-82 is a small molecule indolinone inhibitor of signaling through the growth factor receptors VEGFR and PDGFR.

It was also under development for the treatment of breast cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, fallopian tube cancer, peritoneal cancer, sarcoma and choroidal neovascularization and myopia.

Xcovery Holding overview

Xcovery Holding is a biotechnology company. The company is headquartered in United States.

For a complete picture of Vorolanib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.